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Reproductive and hormonal factors and
mortality among women with colorectal
cancer in the NIH-AARP Diet and Health
Study
H Arem*,1, Y Park2, A S Felix1, A Zervoudakis3, L A Brinton1, C E Matthews1 and M J Gunter4
1

Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Drive, Bethesda, MD 20892, USA;
Division of Public Health Sciences, Washington University School of Medicine in St. Louis, 660 S. Euclid Avenue, Campus Box
8100, St Louis, MO 63110, USA; 3Division of Oncology/Hematology, Winthrop University Hospital, 259 First Street, Mineola,
NY 11501, USA and 4Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, 2 Norfolk
Place, London W2 1PG, UK
2

Background: Although use of menopausal hormone therapy (MHT) and some reproductive factors have been associated with
colorectal cancer (CRC) risk, relations between these factors and survival after CRC diagnosis are unclear.
Methods: Among 2053 post-menopausal women diagnosed with incident CRC in the NIH-AARP Diet and Health Study, we
calculated hazard ratios (HRs) and 95% confidence intervals (CIs) using multivariable Cox proportional hazards regression to test
associations between oral contraceptive (OC) use, menarche age, age at first birth, parity, menopausal age, and MHT use with
all-cause and CRC-specific mortality.
Results: There were 759 deaths (332 CRC-related deaths) over a median follow-up of 7.7 years. We observed no statistically
significant associations between OC use, menarche age, age at first birth, parity, menopausal age, and mortality. Compared with
never MHT use, former use was not associated with mortality, but we found an inverse association among baseline current users,
for both all-cause (HR ¼ 0.79, 95% CI 0.66–0.94) and CRC mortality (0.76, 0.59–0.99).
Conclusion: Future studies should further focus on the mechanisms by which exogenous oestrogen exposure might affect tumour
progression and CRC survival.

There were an estimated 624 340 female colorectal cancer (CRC)
survivors in the United States in 2014 (American Cancer
Society, 2014). This number is projected to grow to over 771 000
by 2024, making female survivors of CRC the second largest group
of female cancer survivors in the United States (American Cancer
Society, 2014). CRC rates are lower among women in the United
States than among men (Brenner et al, 2007), and use of
menopausal hormone therapy (MHT) has been associated with a

30–40% lower risk of CRC, prompting research into the role of
oestrogen in carcinogenesis (Grodstein et al, 1999).
In addition to the well-established association between MHT
use and lower CRC risk (Writing Group for the Women’s
Health Initiative I, 2002), previous literature has explored the
hypotheses of exogenous oestrogen exposure and better survival
after a CRC diagnosis (Persson et al, 1996; Slattery et al, 1999;
Mandelson et al, 2003; Chan et al, 2006; Ritenbaugh et al, 2008;
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Newcomb et al, 2009). However, published results are conflicting,
perhaps owing to small sample sizes and limited information on
type and duration of MHT use. Also, while some studies, including
an analysis in the NIH-AARP cohort (Zervoudakis et al, 2011),
have suggested associations between reproductive factors
(e.g., older age at menopause and older age at birth of first child)
and higher CRC risk, studies on such reproductive factors and
CRC survival are limited (Jacobsen et al, 1995).
Understanding factors that contribute to CRC survival may be useful
to clinicians monitoring survivors and may influence research on
disease progression. In this large, prospective cohort, we hypothesised
that we would confirm previous findings on MHT use and improved
survival; furthermore, we hypothesised that we would observe an
inverse association between reproductive factors that increase oestrogen
exposure and mortality risk among women with CRC.
MATERIALS AND METHODS

Study population. The NIH-AARP Diet and Health Study has
been previously described (Schatzkin et al, 2001). Briefly, the NIHAARP cohort included 566,398 AARP members (aged 50–71
years) who completed a mailed baseline questionnaire in
1995–1996. An additional risk factor questionnaire was sent out
6 months after baseline with more detailed questions on MHT type
and duration of use. Participants resided in one of six US states or
two metropolitan areas. After excluding men, questionnaires
completed by proxy, and individuals with a cancer diagnosis
before baseline or end-stage renal disease, the cohort consisted of
365 255 women who were followed for incident CRC.
Cancer cases were identified by linking cohort members to
eight original state cancer registries and three additional states
through 31 December 2006. Cancer registries provided information on cancer diagnosis date, histology, stage, grade, and
first course of treatment reported within 1 year of diagnosis.
We classified invasive, CRC cases using histology codes from
the International Classification of Diseases for Oncology, third
edition (ICD-O-3 code C180–189, C199, and C209; Fritz, 2000).
Incident cancer identification was estimated to be 90% complete
(Michaud et al, 2005).
After excluding pre-menopausal women (n ¼ 54) and women
diagnosed with in situ or metastatic CRC (n ¼ 417), 2053 invasive
CRCs (resulting in 759 deaths overall, 332 CRC deaths) were
included for analysis. The NIH-AARP Diet and Health Study was
approved by the Special Studies Institutional Review Board of the
US National Cancer Institute.
Mortality ascertainment. Vital status was ascertained annually by
linking the Social Security Administration Death Master File and
the National Death Index Plus through 31 December 2011. We
used ICD-9 and ICD-10 codes to classify deaths due to colon
cancer (ICD-9 153 and 159.0, and ICD-10 C18–C26.0) and rectal
cancer (ICD-9 154.0 and 154.1, and ICD-10 C19–C20). Accuracy
of vital status ascertainment in this cohort is 495% (Hermansen
et al, 2009).
Exposure assessment. The baseline questionnaire queried on
various reproductive and hormonal factors, which we categorised
as follows: age at menopause (o45, 45–49, 50–54, and 55 þ years),
age at first live birth (no births, o20, 20–29, and 30 þ years), age
at menarche (p12 and 13 þ years), parity (nulliparous, 1–2 and
3 þ children), oral contraceptive (OC) use (never/ever), MHT use
(never, former, and current), and years using MHT (o5 and 5 þ ).
Additional analyses with more detailed categorisations for age at
menarche and duration of OC use did not change the study
conclusions; thus, we present categories as indicated above in the
main analyses. Among the women in our sample who completed
the risk factor questionnaire, we had additional information on
www.bjcancer.com | DOI:10.1038/bjc.2015.224
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hormone type (oestrogen only, progestin only, and oestrogen plus
progestin) and duration for 1245 women.
Statistical analysis. We used IVEware 2.0 (Survey Methodology
Program, Ann Arbor, MI, USA, 2002) to impute values for missing
variables, using 10 iterations and five imputations. We estimated
hazard ratios (HRs) and 95% confidence intervals (CIs) using Cox
proportional hazards regression with age as the underlying time
metric. Person-time was calculated from age at diagnosis to death or
censoring. Proc mianalyze was used to combine results from the five
imputed data sets.
In regression models, we included a priori determined
covariates that were associated with the main exposures or
mortality in previous analyses. Final models were adjusted for
years from questionnaire to diagnosis (continuous), body mass
index (18.5–25, 25–30, and 30 þ kg m  2), marital status (married
or living as married, yes/no), smoking status (never, former, and
current), diabetes (yes/no), physical activity (never/rarely, 1–3
times per month, 1–2 times per week, 3–4 times per week, and 5 þ
times per week), tumour stage (localised and regional/distant),
tumour grade (well differentiated, moderately differentiated, and
poorly differentiated), chemotherapy (yes/no), radiation (yes/no),
and surgery (yes/no). We also tested health status in the models,
but inclusion did not change parameter estimates by 410%, and
thus final models are presented without health status adjustment.
Trend tests were performed by coding the exposure categories as
ordinal and treating the variable as linear. Trend tests for parity
and age at first birth were first conducted including all women and
then excluding nulliparous women; trend results did not differ
substantially. Because there may be unaccounted for factors that
distinguish the nulliparous women from those women who have
children, we performed additional analyses comparing women who
never gave birth to those who did.
We also tested associations between the five reproductive factors
of interest and mortality stratified by MHT use to test for residual
confounding by MHT use and to further explore interaction that
was observed in analyses of reproductive factors and CRC
incidence in this cohort (Zervoudakis et al, 2011). We created
additional models with more detailed covariates on MHT type
(oestrogen only, progestin only, and oestrogen plus progestin) and
duration (o5, 5–9, and 10 þ years) in the subset of 1245 women
with data from the risk factor questionnaire. We also performed
analyses stratified by median diagnosis age, median BMI, cancer
site (colon or rectum), status of ovaries (both ovaries removed,
both ovaries intact, or other surgery to ovaries), and natural
menopause (yes/no). We created interaction terms for these
covariates with the exposure of interest and tested for statistical
significance using the Wald test. We tested the proportional
hazards assumption by including an interaction term between
person-time and the exposure of interest, and used the Wald test to
determine statistical significance (all P-interaction values 40.10).
Statistical analyses were performed using SAS 9.3 (SAS Institute
Inc. Cary, NC, USA).
RESULTS

The median time from baseline questionnaire to diagnosis was 5.3
years and median follow-up time was 7.7 years. Women who died
were more likely to have regional/distant stage tumours, poorly
differentiated tumours, and to have received chemotherapy as first
course of treatment (Table 1). Women who died were also more
likely to be physically inactive, current smokers at baseline, and
report worse health status. A greater percentage of women who
died reported never use of MHT and history of diabetes.
We observed a suggested, but not statistically significant, lower
risk of all-cause mortality among women who were 13 þ years old
563
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Table 1. Tumour and baseline characteristics of women with
colorectal cancer in the NIH-AARP Study (n ¼ 2053)
Deaths

Table 1. ( Continued )

Deaths

Non-deaths

Non-deaths

70.0 (5.1)

69.1 (5.6)

Age at menopause, n (%)
o45 years
45–49 years
50–54 years
55 þ years
Missing

Tumour summary stage, n (%)
Localised
Regional/distant
Unknown

168 (22.1)
286 (37.7)
305 (40.2)

459 (35.5)
353 (27.3)
482 (37.3)

Age at menarche, n (%)
o12 years
12 þ years
Missing

383 (50.5)
365 (48.1)
11 (1.5)

610 (47.1)
672 (51.9)
12 (0.9)

Tumour grade at diagnosis, n (%)
Well differentiated
Moderately differentiated
Poorly differentiated
Undifferentiated
Unknown

80
418
158
8
95

167
763
160
11
193

Menopausal hormone therapy use, n (%)
Never
Former
Current
Missing

457
87
214
1

721
114
456
3

Tumour characteristics
Cancer site, n (%)
Colon
Rectal
Mean age at diagnosis, years (s.d.)

First course of treatment, n (%)
Surgery
Chemotherapy
Radiation

561 (73.9)
198 (26.1)

967 (74.7)
327 (25.3)

(10.5)
(55.1)
(20.8)
(1.1)
(12.5)

(12.9)
(59.0)
(12.4)
(0.9)
(14.9)

Oral contraceptive use ever, n (%)
611 (80.5)
256 (33.7)
77 (11.8)

1126 (87.0)
308 (23.8)
87 (8.2)

Race/ethnicity, n (%)
Non-Hispanic White
African American
Other
Missing

690
43
14
12

(90.9)
(5.7)
(1.8)
(1.6)

1125
92
43
34

(86.9)
(7.1)
(3.3)
(2.6)

Body mass index, kg m  2, n (%)
18.5 to o25
25 to o30
30 þ
Missing

266
225
205
63

(35.1)
(29.6)
(27.0)
(8.3)

487
445
298
64

(37.6)
(34.4)
(23.0)
(5.0)

Physical activity, n (%)
Never/rarely
1–3 Times per month
1–2 Times per week
3 þ Times per week
Missing

226
109
149
258
17

(29.8)
(14.4)
(19.6)
(34.0)
(2.2)

303
178
284
512
17

(23.4)
(13.8)
(22.0)
(39.6)
(1.3)

Smoking history, n (%)
Never
Former
Current
Missing

275
305
150
29

(36.2)
(40.2)
(19.8)
(3.8)

574
504
173
43

(44.4)
(39.0)
(13.4)
(3.3)

Education level, n (%)
pHigh school
Some college
College or graduate school
Missing

269
269
181
40

(35.4)
(35.4)
(23.9)
(5.3)

480
432
335
47

(37.1)
(33.4)
(25.9)
(3.6)

Self-reported health, n (%)
Excellent/very good
Good
Fair
Poor
Missing

332
271
119
19
18

(43.7)
(35.7)
(15.7)
(2.5)
(2.4)

652
486
114
19
23

(50.4)
(37.6)
(8.8)
(1.5)
(1.8)

Pre-diagnosis, baseline characteristics

History of colorectal polyps, n (%)

66 (8.7)

99 (7.7)

Parity, n (%)
Nulliparous
1
2
3þ
Missing

111
71
182
382
13

(14.6)
(9.4)
(24.0)
(50.3)
(1.7)

187
134
321
639
13

(14.5)
(10.4)
(24.8)
(49.4)
(1.0)

Age at first birth, n (%)
Never pregnant
o20 years
20–29 years
30 þ years
Missing

103
128
449
58
21

(13.6)
(16.9)
(59.2)
(7.6)
(2.8)

179
215
806
77
17

(13.8)
(16.6)
(62.3)
(6.0)
(1.3)

564

Family history of colon cancer, n (%)

264
172
230
80
13

(34.8)
(22.7)
(30.3)
(10.5)
(1.7)

(60.2)
(11.5)
(28.2)
(0.1)

425
331
401
121
16

(32.8)
(25.6)
(40.0)
(9.4)
(1.2)

(55.7)
(8.8)
(35.2)
(0.2)

229 (30.2)

424 (32.8)

73 (9.6)

139 (10.7)

Diabetes history, n (%)

121 (15.9)

104 (8.0)

Energy adjusted red meat intake
(g per 1000 kcal per day, s.d.)

31.1 (19.7)

30.4 (20.0)

6.8 (19.1)

6.8 (23.0)

Mean alcohol intake, g per day (s.d.)
Abbreviation: s.d. ¼ standard deviation.

at menarche compared with women who were p12 years old
(HR ¼ 0.88, 95% CI 0.76–1.01); No overall associations were found
for age at menopause (regardless of hysterectomy/oophorectomy
status), age at first live birth, parity, or OC use (Table 2). For CRC
mortality, we found no associations between these five reproductive or menstrual factors in our analysis. Additional analyses
comparing nulliparous to parous women showed no significant
associations with mortality.
Compared with women who reported never use of MHT,
former MHT use was not associated with all-cause mortality
(HR ¼ 1.13, 95% CI 0.89–1.43). We also found no association
with CRC-specific death among former MHT users (HR ¼ 0.98,
95% CI 0.68–1.43) compared with never MHT users. However,
among women who reported current MHT use at baseline, we
observed a 21% lower risk of all-cause death (HR ¼ 0.79, 95% CI
0.66–0.94) and a 24% lower risk of CRC death (HR ¼ 0.76, 95%
CI 0.59–0.99).
Analyses of OC use, age at menarche, age at first birth, parity,
and age at menopause stratified by never, former, or current MHT
use showed no statistically significant interactions with all-cause or
CRC-specific death (all P-values 40.1; Figures 1 and 2).
Interaction terms were also not significant regardless of whether
nulliparous women were included in the models.
In analyses stratified by cancer site (colon or rectum), none of
the P-interaction values for the examined exposures were
significant at a Po0.05 level (Table 3). However, for women with
colon cancer, stratified models suggested a non-statistically
significant increased risk of CRC-specific death (HR ¼ 1.58, 95%
CI 0.92–2.70) comparing women age 30 þ years at first birth with
women who gave birth before 20 years of age. This association was
inverse, but not statistically significant, among women with rectal
cancer (HR ¼ 0.38, 95% CI 0.10–1.40).
There also appeared to be differences in associations by cancer
site for MHT use and mortality. Among women with colon cancer,
former and current use compared with never use were not
associated with mortality. However, among women with rectal
cancer, compared with never users, we found no association for
former users, but among current users, we observed a significant,
39% lower risk of all-cause death (HR ¼ 0.61, 95% CI 0.43–0.87)
www.bjcancer.com | DOI:10.1038/bjc.2015.224
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Table 2. Reproductive characteristics, menopausal therapy use, and mortality risk among women with colorectal cancer
(n ¼ 2053)
All-cause mortality
Variable

Colorectal cancer mortality
Crude HR
(95% CI)

Multivariable-adjusted
HR (95% CI)a

111
76
101
38

1.00
0.86 (0.64, 1.16)
1.00 (0.77, 1.31)
1.08 (0.74, 1.57)
0.712

1.00
0.81 (0.60, 1.11)
1.01 (0.77, 1.33)
1.16 (0.79, 1.69)
0.488

0.98 (0.75, 1.28)
1.00
0.93 (0.76, 1.13)
1.04 (0.75, 1.44)
0.971

37
58
199
28

0.86 (0.56, 1.32)
1.00
0.97 (0.72, 1.30)
1.30 (0.83, 2.05)
0.414

0.82 (0.52, 1.28)
1.00
0.99 (0.73, 1.34)
1.19 (0.73, 1.92)
0.623

1.00
0.88 (0.76, 1.01)
0.075

1.00
0.88 (0.76, 1.01)
0.075

170
156

1.00
0.87 (0.70, 1.09)
0.234

1.00
0.87 (0.69, 1.09)
0.232

1.15 (0.91, 1.45)
1.00
1.05 (0.90, 1.24)
0.537

1.04 (0.81, 1.33)
1.00
0.98 (0.83, 1.15)
0.838

43
116
168

0.91 (0.63, 1.31)
1.00
1.01 (0.80, 1.28)
0.918

0.81 (0.54, 1.22)
1.00
0.93 (0.73, 1.19)
0.625

1.00
0.94 (0.80, 1.10)
0.435

1.00
0.97 (0.82, 1.14)
0.703

218
107

1.00
0.93 (0.73, 1.18)
0.536

1.00
0.95 (0.74, 1.22)
0.679

1.00
1.13 (0.89, 1.42)
0.78 (0.66–0.92)

1.00
1.13 (0.89, 1.43)
0.79 (0.66, 0.94)

183
36
98

1.00
1.03 (0.72, 1.47)
0.76 (0.59, 0.97)

1.00
0.98 (0.68, 1.43)
0.76 (0.59, 0.99)

Crude HR
(95% CI)

Multivariable-adjusted
HR (95% CI)a

1.00
0.82 (0.68, 1.00)
0.94 (0.79, 1.12)
0.97 (0.76, 1.25)
0.714

1.00
0.81 (0.67, 0.99)
0.95 (0.79, 1.14)
1.04 (0.81, 1.34)
0.943

1.02 (0.78, 1.33)
1.00
0.91 (0.74, 1.11)
1.11 (0.81, 1.52)
0.899

383
365

111
253
382

Deaths (n)

Deaths (n)

Age at menopause, years
o45
45–49
50–54
55 þ
P-trend

264
172
230
80

Age at first live birth, yearsb
No births
o20
20–29
30 þ
P-trend

103
128
449
58

Age at menarche, years
p12
13 þ
P-trend

Parityb
Nulliparous
1–2
3þ
P-trend

Oral contraceptive use
Never
Ever
P-trend

514
229

Menopausal hormone therapy
Never
Former
Current

457
87
214

Abbreviations: CI ¼ confidence interval; HR ¼ hazard ratio.
a
Multivariable-adjusted models used age as the underlying time metric and were adjusted for years from questionnaire to diagnosis (continuous), body mass index (18.5–25, 25–30, and
30 þ kg m  2), marital status (married or living as married, yes/no), smoking status (never, former, and current), diabetes (yes/no), physical activity (never/rarely, 1–3 times per month, 1–2 times
per week, 3–4 times per week, and 5 þ times per week), tumour stage, tumour grade (well differentiated, moderately differentiated, and poorly differentiated), chemotherapy (yes/no), radiation
(yes/no), and surgery (yes/no).
b
Trend tests excluded nulliparous women.

P-interactions

P-interactions
Use of oral contraceptives

0.488

Later age at menarche
Older age at first birth

Current
Former
Never

Use of oral contraceptives

0.519

Later age at menarche

0.326

Older age at first birth

Parity

0.423

Later at age menopause

0.432

0.5
1.0
1.5
2.0
2.5
Hazard ratios and 95% confidence intervals for mortality

0.186
Current
Former
Never

0.376
0.678

Parity

0.536

Later at age menopause

0.404
0.5

1.0
1.5
2.0
Hazard ratios and 95% confidence
intervals for CRC mortality

2.5

Figure 1. Reproductive factors and risk of all-cause mortality, stratified
by baseline use of hormone replacement therapy. Categories for age
at menarche, age at first birth, parity, and age at menopause were
ranked in an ordinal fashion and treated as linear; for age at first birth
and parity nulliparous women were excluded from models. Models
were adjusted for years from questionnaire to diagnosis, body mass
index, marital status, smoking status, diabetes, physical activity, tumour
stage, tumour grade, chemotherapy, radiation, and surgery.

Figure 2. Reproductive factors and risk of CRC mortality, stratified by
baseline use of hormone replacement therapy. Categories for age at
menarche, age at first birth, parity, and age at menopause were ranked
in an ordinal fashion and treated as linear; for age at first birth and
parity, nulliparous women were excluded from models. Models were
adjusted for years from questionnaire to diagnosis, body mass index,
marital status, smoking status, diabetes, physical activity, tumour stage,
tumour grade, chemotherapy, radiation, and surgery.

and a 52% lower risk of CRC death (HR ¼ 0.48, 95% CI 0.25–0.92).
However, multiplicative interaction was not statistically significant
by cancer site (Pinteraction ¼ 0.980 for all-cause mortality and
Pinteraction ¼ 0.531 for CRC mortality).

Among the subset of women with information on MHT
preparation, the inverse associations appeared to be stronger
among women using oestrogen only compared with women using
combined oestrogen–progestin therapy, although smaller numbers

www.bjcancer.com | DOI:10.1038/bjc.2015.224
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Table 3. Reproductive characteristics, menopausal hormone use, and mortality risk among women with colorectal cancer,
stratified by colon (n ¼ 1528) or rectal (n ¼ 525) cancera
Colon cancer
Variable

Rectal cancer

All-cause mortality
HR (95% CI)

CRC
deaths (n)

1.00
0.82 (0.65, 1.03)
0.96 (0.78, 1.19)
1.06 (0.79, 1.42)
0.855
0.978

92
63
80
32

1.00
0.80 (0.58, 1.12)
1.00 (0.74, 1.36)
1.19 (0.78, 1.80)
0.496
0.767

68
42
62
21

1.00
0.80 (0.54, 1.18)
0.93 (0.65, 1.33)
0.91 (0.55, 1.52)
0.729

19
13
21
6

1.00
0.91 (0.43, 1.90)
1.14 (0.59, 2.21)
0.83 (0.31, 2.21)
0.991

1.00 (0.72, 1.39)
1.00
0.99 (0.78, 1.26)
1.29 (0.90, 1.87)
0.990

30
43
166
25

0.97 (0.57, 1.65)
1.00
1.22 (0.86, 1.74)
1.58 (0.92, 2.70)
0.109

34
33
115
10

0.82 (0.49, 1.36)
1.00
0.74 (0.49, 1.12)
0.55 (0.27, 1.15)

7
15
33
3

0.43 (0.17, 1.07)
1.00
0.42 (0.22, 0.82)
0.38 (0.10, 1.40)

287
267

1.00
0.89 (0.75, 1.05)
0.164
0.925

144
123

1.00
0.84 (0.66, 1.08)
0.175
0.503

96
98

1.00
0.86 (0.65, 1.15)
0.324

26
33

1.00
1.02 (0.59, 1.78)
0.941

76
189
290

1.00 (0.76, 1.32)
1.00
0.95 (0.78, 1.15)
0.957

35
94
140

0.82 (0.53, 1.26)
1.00
0.92 (0.70, 1.21)
0.873

35
64
92

1.07 (0.66, 1.74)
1.00
1.02 (0.72, 1.42)

8
22
28

0.73 (0.29, 1.83)
1.00
0.81 (0.45, 1.46)

1.00
0.99 (0.81, 1.20)
0.890
0.456

180
87

1.00
0.95 (0.72, 1.26)
0.734
0.614

130
62

1.00
0.90 (0.64, 1.25)
0.528

38
20

1.00
0.89 (0.49, 1.60)
0.692

147
29
84

1.00
1.02 (0.68, 1.53)
0.84 (0.64, 1.10)
0.531

112
24
51

1.00
1.36 (0.86, 2.15)
0.61 (0.43, 0.87)

36
7
14

1.00
0.93 (0.40, 2.17)
0.48 (0.25, 0.92)

Deaths (n)

CRC mortality
HR (95% CI) Deaths (n)

All-cause mortality
HR (95% CI)

CRC
CRC mortality
deaths (n) HR (95% CI)

Age at menopause, years
o45
45–49
50–54
55 þ
P-trend
P-interaction

196
130
168
59

Age at first live birth, years
No births
o20
20–29
30 þ
P-interaction

69
95
334
48

Age at menarche, years
p12
13 þ
P-trend
P-interaction

Parity
Nulliparous
1–2
3þ
P-interaction

Oral contraceptive use
Never
Ever
P-trend
P-interaction

384
167

Menopausal hormone therapy
Never
Former
Current
P-interaction

314
62
163

1.00
1.03 (0.78, 1.37)
0.86 (0.71, 1.05)
0.980

Abbreviations: CI ¼ confidence interval; CRC ¼ colorectal cancer; HR: ¼ hazard ratio. All models used age as the underlying time metric and were adjusted for years from questionnaire to
diagnosis (continuous), body mass index (18.5–25, 25–30, and 30 þ kg m  2), marital status (married or living as married, yes/no), smoking status (never, former, and current), diabetes (yes/no),
physical activity (never/rarely, 1–3 times per month, 1–2 times per week, 3–4 times per week, and 5 þ times per week), tumour stage, tumour grade (well differentiated, moderately
differentiated, and poorly differentiated), chemotherapy (yes/no), radiation (yes/no), and surgery (yes/no).

may have led to a lack of statistical significance (Table 4). To assess
whether tumour stage and grade differed by MHT usage status, we
cross-tabulated the factors and found that the percentage of never,
former, and current MHT users were similar by both tumour stage
and grade.
We did not find evidence of interaction by median diagnosis
age (69.8 years), median BMI (26.2 kg m  2), status of ovaries, or
natural menopause status (all P-values 40.1).

DISCUSSION

In this study of 2 053 women with CRC, reproductive and
menstrual factors were not associated with mortality, while current,
but not former, baseline MHT use was associated with lower allcause and CRC mortality risks.
A previous analysis in this cohort that examined reproductive
history and CRC incidence reported increased risks with older age
at menopause (55 þ vs o40 years old, HR ¼ 1.50, 95% CI
1.23–1.83) and age at first birth (30 þ vs p19 years old,
HR ¼ 1.26, 95% CI 1.01–1.58); an inverse association between
age at menarche (15 þ vs 11–12 years old, HR ¼ 0.73, 95% CI
566

0.57–0.94) and lower risk of CRC was observed only
among those women with no history of MHT use (Zervoudakis
et al, 2011). We did not find evidence of these patterns for
mortality overall or due to CRC. The previous findings in this
cohort, in combination with other prospective studies on age at
first birth and CRC risk, are equivocal, as two previous studies
showed no association (Tamakoshi et al, 2004; Lin et al, 2007), and
a third study showed a statistically significant increased risk of
developing CRC with older age at first birth (Martinez et al, 1997).
One hypothesis for the observed association between reproductive
factors and CRC risk is that pregnancy reduces bile acid synthesis,
which affects carcinogenesis (McMichael and Potter, 1980). To our
knowledge, previous studies have not examined these reproductive
factors and mortality among CRC survivors.
Previous studies on MHT and CRC survival have reported
variable results. Some studies have shown a B30% lower mortality
risk among women reporting oestrogen-only therapy, but not
among women using combined oestrogen plus progestin therapy
(Persson et al, 1996; Chan et al, 2006). The Nurses’ Health Study
found 36% lower risk among current as opposed to never users,
which differed by duration of use; current use o5 years was
associated with a mortality HR (95% CI) of 0.39 (0.23–0.67),
whereas current use for 5 þ years was nonsignificant (0.83, 0.58–1.18;
www.bjcancer.com | DOI:10.1038/bjc.2015.224
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Table 4. Menopausal hormone therapy and mortality risk
among women with colorectal cancer by preparation
(n ¼ 1245)
Overall mortality

CRC mortality
No.
deaths

Multivariableadjusted HR
(95% CI)a

0.82 (0.65–1.04)

43/325

0.75 (0.52–1.08)

21/51

1.14 (0.72–1.81)

10/51

1.03 (0.52–2.04)

Continuous
EPT

27/99

0.77 (0.51–1.15)

12/99

0.64 (0.35–1.17)

Unknown
type

40/128

0.86 (0.61–1.21)

20/128

0.91 (0.55–1.49)

Variable

No.
deaths/
total

Multivariableadjusted HR
(95% CI)a

Never users

246/642

1.00

Estrogen
only

104/325

Sequential
EPT

Abbreviations: CI ¼ confidence interval; HR ¼ hazard ratio.
a
Multivariable-adjusted models were adjusted for years from questionnaire to diagnosis
(continuous), body mass index (18.5–25, 25–30, 30 þ kg m  2), marital status (married or
living as married, yes/no), smoking status (never, former, current), diabetes (yes/no), physical
activity (never/rarely, 1–3 times/month, 1–2 times/week, 3–4 times/week, 5 þ times/week),
tumour stage, tumour grade (well differentiated, moderately differentiated, poorly
differentiated), chemotherapy (yes/no), radiation (yes/no), and surgery (yes/no).

Chan et al, 2006). Approximately 75% of the NHS study
population reported use of oestrogen alone, whereas 25% reported
oestrogen plus progestin use, but MHT type-stratified analyses
were not presented. Two other studies without information on type
of MHT have shown an B40% lower risk of mortality among
MHT users compared with non-users (Slattery et al, 1999;
Mandelson et al, 2003). In contrast, a study in the Women’s
Health Initiative (111 CRC cases) showed no association between
conjugated equine oestrogen use and CRC mortality (Ritenbaugh
et al, 2008). Our findings on MHT use and survival are generally
consistent with those found in the Nurses’ Health Study, suggesting
that use of MHT is associated with lower CRC mortality. Still, it is
possible that lower mortality among MHT users could be due to
better health surveillance of these women.
Mechanistic data support a role for endogenous oestrogen in
CRC tumorigenesis and prognosis (Sato et al, 2009). In vitro
studies have shown that oestrogen affects cell growth in colon
cancer cell lines (Singh et al, 1994), and that oestrogen receptor-b
(ER-b) protein expression is lower in malignant colon tissue
(Foley et al, 2000; Barzi et al, 2013). A review of oestrogen-related
molecular pathways and CRC suggested that the loss of ER-b
expression during tumorigenesis can be countered by oestrogen
ligands, MHT, or soy products, which perhaps may explain the
importance of recent timing of hormone use in the protective
association with CRC survival (Barzi et al, 2013). Previous studies
in humans have also shown increased insulin sensitivity in
response to oral equine oestrogens or transdermal E2 patches
(Lindheim et al, 1994).
Strengths of this study include the prospective collection of data,
which minimises recall bias. Our large sample size permitted
separate examination of colon and rectal cancers to identify
whether associations with these hormonal and menstrual factors
differed by cancer site. We also had information on numerous
other CRC risk and prognostic factors, as well as CRC tumour
characteristics and treatment data. Limitations of this study include
that only a subset of the cohort had detailed information on type of
MHT, precluding detailed analyses of both type and duration of
use. Also, in our study, we had only a single assessment of MHT
use, which may have changed over the follow-up period.
Future studies may seek to further differentiate between
mortality risk associated with specific MHT preparations, and
further focus on the mechanisms through which recent oestrogen
exposures may have a role in colorectal tumour progression.
www.bjcancer.com | DOI:10.1038/bjc.2015.224
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